The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set ...

With concerns mounting and speculation swirling, the particulars of President Donald Trump’s much-touted “Liberation Day” ...

Discover 10 top high-yield dividend stocks for April 2025. With a 5.30% yield & 8.33% growth rate, learn how to build wealth ...

The latest trading session saw Pfizer (PFE) ending at $24.70, denoting a +0.65% adjustment from its last day's close. This change lagged the S&P 500's 0.67% gain on the day. Meanwhile, the Dow ...

Major pharmaceutical companies reap most of their profits in the U.S. but shift their tax burdens to low-tax havens such as ...

Vaccines are a powerful tool of modern medicine, protecting you from diseases that once caused widespread suffering and death ...

With the recently announced layoffs of 3,500 FDA staffers and exits of branch directors Patrizia Cavazzoni and Peter Marks, ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its ...

(Reuters) -Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation ...